

# Paolo Fagone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5599312/publications.pdf>

Version: 2024-02-01

112  
papers

5,196  
citations

101543

36  
h-index

95266

68  
g-index

115  
all docs

115  
docs citations

115  
times ranked

8372  
citing authors

#	ARTICLE	IF	CITATIONS
1	The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19. <i>Drug Discovery Today</i> , 2022, 27, 848-856.	6.4	45
2	Neuroprotective Effects of Myrtenal in an Experimental Model of Dementia Induced in Rats. <i>Antioxidants</i> , 2022, 11, 374.	5.1	7
3	Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimer's Disease Patients and In Silico Prediction of Potential Repurposable Drugs. <i>Genes</i> , 2022, 13, 703.	2.4	3
4	Computational Analysis of Pathogenetic Pathways in Alzheimer's Disease and Prediction of Potential Therapeutic Drugs. <i>Brain Sciences</i> , 2022, 12, 827.	2.3	3
5	Characterization of a small molecule modulator of inflammatory cytokine production. <i>Translational Medicine Communications</i> , 2022, 7, .	1.4	0
6	Macrophage Migration Inhibitory Factor (MIF) and Its Homologue D-Dopachrome Tautomerase (DDT) Inversely Correlate with Inflammation in Discoid Lupus Erythematosus. <i>Molecules</i> , 2021, 26, 184.	3.8	11
7	Cognitive Decline in Rheumatoid Arthritis: Insight into the Molecular Pathogenetic Mechanisms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1185.	4.1	20
8	Identification of Common Pathogenetic Processes between Schizophrenia and Diabetes Mellitus by Systems Biology Analysis. <i>Genes</i> , 2021, 12, 237.	2.4	13
9	A Network Medicine Approach for Drug Repurposing in Duchenne Muscular Dystrophy. <i>Genes</i> , 2021, 12, 543.	2.4	5
10	Altered Expression of TSPAN32 during B Cell Activation and Systemic Lupus Erythematosus. <i>Genes</i> , 2021, 12, 931.	2.4	3
11	Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	19
12	Transcriptomic Data Analysis Reveals a Down-Expression of Galectin-8 in Schizophrenia Hippocampus. <i>Brain Sciences</i> , 2021, 11, 973.	2.3	2
13	Therapeutic Potential of Alpha-Lipoic Acid in Viral Infections, including COVID-19. <i>Antioxidants</i> , 2021, 10, 1294.	5.1	19
14	Pathogenic contribution of the Macrophage migration inhibitory factor family to major depressive disorder and emerging tailored therapeutic approaches. <i>Journal of Affective Disorders</i> , 2020, 263, 15-24.	4.1	37
15	In Silico and In Vivo Analysis of IL37 in Multiple Sclerosis Reveals Its Probable Homeostatic Role on the Clinical Activity, Disability, and Treatment with Fingolimod. <i>Molecules</i> , 2020, 25, 20.	3.8	22
16	Effects of Combined Administration of Imatinib and Sorafenib in a Murine Model of Liver Fibrosis. <i>Molecules</i> , 2020, 25, 4310.	3.8	6
17	Comprehensive Analysis of RNA-Seq Gene Expression Profiling of Brain Transcriptomes Reveals Novel Genes, Regulators, and Pathways in Autism Spectrum Disorder. <i>Brain Sciences</i> , 2020, 10, 747.	2.3	45
18	Upregulation of Tolerogenic Pathways by the Hydrogen Sulfide Donor GYY4137 and Impaired Expression of H2S-Producing Enzymes in Multiple Sclerosis. <i>Antioxidants</i> , 2020, 9, 608.	5.1	9

#	ARTICLE	IF	CITATIONS
19	Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8803.	4.1	7
20	Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. <i>Autoimmunity Reviews</i> , 2020, 19, 102571.	5.8	92
21	Exploratory Analysis of iPSCs-Derived Neuronal Cells as Predictors of Diagnosis and Treatment of Alzheimer Disease. <i>Brain Sciences</i> , 2020, 10, 166.	2.3	12
22	The cytokine network in the pathogenesis of major depressive disorder. Close to translation?. <i>Autoimmunity Reviews</i> , 2020, 19, 102504.	5.8	52
23	Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?. <i>Molecules</i> , 2020, 25, 1194.	3.8	25
24	Impaired Expression of Tetraspanin 32 (TSPAN32) in Memory T Cells of Patients with Multiple Sclerosis. <i>Brain Sciences</i> , 2020, 10, 52.	2.3	13
25	The Role of Macrophage Migration Inhibitory Factor in Alzheimer's Disease: Conventionally Pathogenetic or Unconventionally Protective?. <i>Molecules</i> , 2020, 25, 291.	3.8	31
26	The Dichotomic Role of Macrophage Migration Inhibitory Factor in Neurodegeneration. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3023.	4.1	15
27	Transcriptomic Analysis Reveals Abnormal Expression of Prion Disease Gene Pathway in Brains from Patients with Autism Spectrum Disorders. <i>Brain Sciences</i> , 2020, 10, 200.	2.3	2
28	Meta-Analysis of Transcriptomic Data of Dorsolateral Prefrontal Cortex and of Peripheral Blood Mononuclear Cells Identifies Altered Pathways in Schizophrenia. <i>Genes</i> , 2020, 11, 390.	2.4	14
29	Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). <i>International Journal of Molecular Medicine</i> , 2020, 46, 903-912.	4.0	73
30	Transcriptomic analysis of COVID-19 lungs and bronchoalveolar lavage fluid samples reveals predominant B cell activation responses to infection. <i>International Journal of Molecular Medicine</i> , 2020, 46, 1266-1273.	4.0	30
31	Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players. <i>Oncology Letters</i> , 2020, 20, 332.	1.8	8
32	Transcriptomic analysis reveals moderate modulation of macrophage migration inhibitory factor superfamily genes in alcohol use disorders. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 1755-1762.	1.8	4
33	Retrospective follow-up analysis of the transcriptomic patterns of cytokines, cytokine receptors and chemokines at preconception and during pregnancy, in women with post-partum depression. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 2055-2062.	1.8	23
34	Effects of GIT-27NO, a NO-donating compound, on hepatic ischemia/reperfusion injury. <i>International Journal of Immunopathology and Pharmacology</i> , 2019, 33, 205873841986273.	2.1	3
35	Characterization of the Pathophysiological Role of CD47 in Uveal Melanoma. <i>Molecules</i> , 2019, 24, 2450.	3.8	29
36	Upregulation of IL-1 Receptor Antagonist in a Mouse Model of Migraine. <i>Brain Sciences</i> , 2019, 9, 172.	2.3	26

#	ARTICLE	IF	CITATIONS
37	Upregulated Expression of Macrophage Migration Inhibitory Factor, Its Analogue D-Dopachrome Tautomerase, and the CD44 Receptor in Peripheral CD4 T Cells from Clinically Isolated Syndrome Patients with Rapid Conversion to Clinical Defined Multiple Sclerosis. <i>Medicina (Lithuania)</i> , 2019, 55, 667.	2.0	26
38	Overexpression of Macrophage Migration Inhibitory Factor and Its Homologue D-Dopachrome Tautomerase as Negative Prognostic Factor in Neuroblastoma. <i>Brain Sciences</i> , 2019, 9, 284.	2.3	26
39	Prediction of PD-L1 Expression in Neuroblastoma via Computational Modeling. <i>Brain Sciences</i> , 2019, 9, 221.	2.3	22
40	Modulation of Tetraspanin 32 (TSPAN32) Expression in T Cell-Mediated Immune Responses and in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4323.	4.1	23
41	Identification of CD4+ T cell biomarkers for predicting the response of patients with relapsingâ€‘remitting multiple sclerosis to natalizumab treatment. <i>Molecular Medicine Reports</i> , 2019, 20, 678-684.	2.4	27
42	Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF. <i>Journal of Neuroimmunology</i> , 2019, 332, 224-232.	2.3	29
43	KCNMA1 Expression is Downregulated in Colorectal Cancer via Epigenetic Mechanisms. <i>Cancers</i> , 2019, 11, 245.	3.7	23
44	Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets. <i>Frontiers in Oncology</i> , 2019, 9, 1145.	2.8	36
45	Effects of Treatment with the Hypomethylating Agent 5-aza-2â€‘deoxycytidine in Murine Type II Collagen-Induced Arthritis. <i>Pharmaceuticals</i> , 2019, 12, 174.	3.8	17
46	Transcriptomic Analysis Reveals Involvement of the Macrophage Migration Inhibitory Factor Gene Network in Duchenne Muscular Dystrophy. <i>Genes</i> , 2019, 10, 939.	2.4	16
47	Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets. <i>Drug Discovery Today</i> , 2019, 24, 428-439.	6.4	74
48	Differential modulation and prognostic values of immune-escape genes in uveal melanoma. <i>PLoS ONE</i> , 2019, 14, e0210276.	2.5	45
49	Naturally occurring compounds in differentiation based therapy of cancer. <i>Biotechnology Advances</i> , 2018, 36, 1622-1632.	11.7	31
50	Involvement of the Nrf2/HOâ€‘1/CO axis and therapeutic intervention with the COâ€‘releasing molecule CORMâ€‘A1, in a murine model of autoimmune hepatitis. <i>Journal of Cellular Physiology</i> , 2018, 233, 4156-4165.	4.1	47
51	Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. <i>Oncotarget</i> , 2018, 9, 8263-8277.	1.8	75
52	Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences. <i>Journal of Neuroimmunology</i> , 2018, 322, 46-56.	2.3	69
53	Gasotransmitters and the immune system: Mode of action and novel therapeutic targets. <i>European Journal of Pharmacology</i> , 2018, 834, 92-102.	3.5	50
54	The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimerâ€™s Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2018, 19, 831.	4.1	132

#	ARTICLE	IF	CITATIONS
55	Overexpression of macrophage migration inhibitory factor and functionally related genes, D $\alpha$ DT, CD74, CD44, CXCR2 and CXCR4, in glioblastoma. <i>Oncology Letters</i> , 2018, 16, 2881-2886.	1.8	51
56	Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis. <i>Journal of Neuroimmunology</i> , 2018, 321, 41-48.	2.3	13
57	Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach. <i>Oncotarget</i> , 2018, 9, 17951-17970.	1.8	60
58	Identification of novel chemotherapeutic strategies for metastatic uveal melanoma. <i>Scientific Reports</i> , 2017, 7, 44564.	3.3	44
59	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFN $\gamma$ Signaling. <i>Cancer Research</i> , 2017, 77, 4562-4566.	0.9	39
60	HIV protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?. <i>International Journal of Cancer</i> , 2017, 140, 1713-1726.	5.1	63
61	Standardized bovine colostrum derivative impedes development of type 1 diabetes in rodents. <i>Immunobiology</i> , 2017, 222, 272-279.	1.9	6
62	Effects of Synthetic Anti-Inflammatory Sterol in CB3V-Induced Myocarditis: A Morphological Study on Heart Muscle Tissue. <i>Journal of Functional Morphology and Kinesiology</i> , 2016, 1, 69-89.	2.4	10
63	CD4+ T-cell gene expression of healthy donors, HIV-1 and elite controllers: Immunological chaos. <i>Cytokine</i> , 2016, 83, 127-135.	3.2	15
64	Induction of OAS gene family in HIV monocyte infected patients with high and low viral load. <i>Antiviral Research</i> , 2016, 131, 66-73.	4.1	42
65	Vitamin D3 inhibits TNF $\alpha$ -induced latent HIV reactivation in J-LAT cells. <i>Molecular and Cellular Biochemistry</i> , 2016, 418, 49-57.	3.1	12
66	Expression of DNA methylation genes in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 290, 66-69.	2.3	17
67	Emerging therapeutic targets for the treatment of hepatic fibrosis. <i>Drug Discovery Today</i> , 2016, 21, 369-375.	6.4	71
68	Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 306-315.	2.5	19
69	Cyclin D1 in pediatric neuroblastic tumors: A microarray analysis. <i>Acta Histochemica</i> , 2015, 117, 820-823.	1.8	4
70	Identification of novel targets for the diagnosis and treatment of liver fibrosis. <i>International Journal of Molecular Medicine</i> , 2015, 36, 747-752.	4.0	46
71	The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K. <i>Leukemia Research</i> , 2015, 39, 1088-1095.	0.8	25
72	Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity. <i>Cancer Research</i> , 2015, 75, 3747-3759.	0.9	93

#	ARTICLE	IF	CITATIONS
73	Carbon monoxide-releasing molecule-A1 (CORM-A1) improves clinical signs of experimental autoimmune uveoretinitis (EAU) in rats. <i>Clinical Immunology</i> , 2015, 157, 198-204.	3.2	33
74	Cyclin D1 and Ewing's sarcoma/PNET: A microarray analysis. <i>Acta Histochemica</i> , 2015, 117, 824-828.	1.8	7
75	Acceleration of SLE-like syndrome development in NZBxNZW F1 mice by beta-glucan. <i>Lupus</i> , 2014, 23, 407-411.	1.6	9
76	Hypomethylating Agent 5-azacitidine (DAC) Ameliorates Multiple Sclerosis in Mouse Models. <i>Journal of Cellular Physiology</i> , 2014, 229, 1918-1925.	4.1	45
77	VGX1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus. <i>Immunology</i> , 2014, 142, 594-602.	4.4	37
78	Immune escape mechanisms associated with tumor recurrence after adoptive cell transfer immunotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 3054-3054.	1.6	0
79	Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 112, 63-69.	2.5	14
80	Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013, 261, 82-86.	2.3	45
81	Apotransferrin inhibits interleukin-2 expression and protects mice from experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2013, 262, 72-78.	2.3	7
82	Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2013, 259, 55-65.	2.3	9
83	No-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST ÅĖLIJA NESITNOÅĖLIJSKOG KARCINOMA PLUÅĖA RAZLIÅĖITE OSETUIVOSTI NA DOKSORUBICIN. <i>Journal of Medical Biochemistry</i> , 2013, 32, 406-416.	1.7	2
84	Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. <i>Cell Cycle</i> , 2012, 11, 1174-1182.	2.6	14
85	BRAF inhibition improves tumor recognition by the immune system. <i>Oncolmmunology</i> , 2012, 1, 1476-1483.	4.6	82
86	Therapeutic Potential of Nitric Oxide-Modified Drugs in Colon Cancer Cells. <i>Molecular Pharmacology</i> , 2012, 82, 700-710.	2.3	28
87	Modulation of heat shock proteins during macrophage differentiation. <i>Inflammation Research</i> , 2012, 61, 1131-1139.	4.0	27
88	Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. <i>Oncology Reports</i> , 2012, 28, 682-688.	2.6	18
89	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. <i>Oncotarget</i> , 2012, 3, 1068-1111.	1.8	279
90	17ÅĖ-Ethynyl-androst-5-ene-3ÅĖ,17ÅĖ-triol (HE3286) Is Neuroprotective and Reduces Motor Impairment and Neuroinflammation in a Murine MPTP Model of Parkinson's Disease. <i>Parkinson's Disease</i> , 2012, 2012, 1-8.	1.1	7

#	ARTICLE	IF	CITATIONS
91	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. <i>Oncotarget</i> , 2012, 3, 954-987.	1.8	244
92	Therapeutic potential of carbon monoxide in multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2012, 167, 179-187.	2.6	55
93	The immunobiology of apotransferrin in type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2012, 169, 244-252.	2.6	6
94	Advances in Targeting Signal Transduction Pathways. <i>Oncotarget</i> , 2012, 3, 1505-1521.	1.8	41
95	In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. <i>Cell Cycle</i> , 2011, 10, 492-499.	2.6	47
96	Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. <i>Cytokine</i> , 2011, 55, 165-167.	3.2	41
97	Influence of lactoferrin in preventing preterm delivery: A pilot study. <i>Molecular Medicine Reports</i> , 2011, 5, 162-6.	2.4	23
98	Phase II study of the antiretroviral activity and safety of the glucocorticoid receptor antagonist mifepristone in HIV-1-infected patients. <i>International Journal of Molecular Medicine</i> , 2011, 28, 437-42.	4.0	4
99	Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1. <i>Clinical and Experimental Immunology</i> , 2011, 163, 368-374.	2.6	65
100	Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination. <i>Gene Therapy</i> , 2011, 18, 1070-1077.	4.5	52
101	Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. <i>Leukemia</i> , 2011, 25, 1064-1079.	7.2	190
102	Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. <i>Leukemia</i> , 2011, 25, 1080-1094.	7.2	232
103	mTOR as a multifunctional therapeutic target in HIV infection. <i>Drug Discovery Today</i> , 2011, 16, 715-721.	6.4	90
104	HE3286, an orally bioavailable synthetic analogue of an active DHEA metabolite suppresses spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse. <i>European Journal of Pharmacology</i> , 2011, 658, 257-262.	3.5	9
105	HIV-Mediated Phosphatidylinositol 3-Kinase/Serine/Threonine Kinase Activation in APCs Leads to Programmed Death-1 Ligand Upregulation and Suppression of HIV-Specific CD8 T Cells. <i>Journal of Immunology</i> , 2011, 187, 2932-2943.	0.8	33
106	A DNA Vaccine against Chikungunya Virus Is Protective in Mice and Induces Neutralizing Antibodies in Mice and Nonhuman Primates. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e928.	3.0	155
107	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , 2011, 3, 192-222.	3.1	520
108	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. <i>Oncotarget</i> , 2011, 2, 135-164.	1.8	509

#	ARTICLE	IF	CITATIONS
109	Specific and Strain-Independent Effects of Dexamethasone in the Prevention and Treatment of Experimental Autoimmune Encephalomyelitis in Rodents. <i>Scandinavian Journal of Immunology</i> , 2010, 72, 396-407.	2.7	26
110	Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon- $\gamma$ secretion by antigen-specific CD8 T cells. <i>Immunology</i> , 2009, 128, e612-20.	4.4	35
111	HIV-1 Vpr: Regulator of Viral Survival. <i>Current HIV Research</i> , 2009, 7, 153-162.	0.5	7
112	Efficacy of Intracolonic Administration of Low-Molecular-Weight Heparin CB-01-05, Compared to Other Low-Molecular-Weight Heparins and Unfractionated Heparin, in Experimentally Induced Colitis in Rat. <i>Digestive Diseases and Sciences</i> , 2008, 53, 3170-3175.	2.3	23